Asterias, Cancer Research UK ink deal for new lung cancer vaccine
As part of the deal, Asterias will complete development of the manufacturing process for AST-VAC2, after which CRT will produce the vaccine and conduct the Phase I/II clinical
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The trial is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of G1T28-1 in healthy volunteers, who are currently being enrolled in the Netherlands. The company is conducting
Outsourcing facilities were created under the federal Drug Quality and Security Act (DQSA) enacted in November 2013. Under the agreement, Cantrell Drug Company will prepare sterile compounded medications
The funding was pledged today by the UK Foreign Office Minister responsible for Africa, James Duddridge, and South Africa’s Minister for Science and Technology, Naledi Pandor, at an